Skip to main content

Table 1 Neoadjuvant systemic treatment regimens

From: The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy

Treatment regimen

n

4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d)

37

4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 4 × docetaxel (175 mg/m2 q21d)

256

4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 4 × docetaxel (175 mg/m2 q21d) + 4 × Herceptin (6 mg/kg q21d)a

26

4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 12 × paclitaxel (80 mg/m2 weekly)

7

4 × epirubicin/docetaxel (60/75 mg/m2 q21d)

25

6 × doxorubicin/cyclophosphamide/docetaxel (50/500/75 mg/m2 q21d)

29

6 × gemcitabine d1 + 8/epirubicin d1/docetaxel d1 (800/90/75 mg/m2 q21d)

20

  1. aLoading dose: 8 mg/kg.